As Biotechnology companies, Adial Pharmaceuticals Inc. (NASDAQ:ADIL) and Matinas BioPharma Holdings Inc. (NYSEAMERICAN:MTNB) are our subject to contrast. And more specifically their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals Inc.	N/A	0.00	11.63M	-1.87	0.00
Matinas BioPharma Holdings Inc.	N/A	1017.82	14.87M	-0.16	0.00

Demonstrates Adial Pharmaceuticals Inc. and Matinas BioPharma Holdings Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 shows us Adial Pharmaceuticals Inc. and Matinas BioPharma Holdings Inc.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals Inc.	0.00%	0%	-775.4%
Matinas BioPharma Holdings Inc.	0.00%	0%	-104.5%

Liquidity

16.2 and 16.2 are the respective Current Ratio and a Quick Ratio of Adial Pharmaceuticals Inc. Its rival Matinas BioPharma Holdings Inc.’s Current and Quick Ratios are 2.9 and 2.9 respectively. Adial Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Matinas BioPharma Holdings Inc.

Institutional and Insider Ownership

The shares of both Adial Pharmaceuticals Inc. and Matinas BioPharma Holdings Inc. are owned by institutional investors at 2.8% and 11.7% respectively. 34.27% are Adial Pharmaceuticals Inc.’s share owned by insiders. Competitively, Matinas BioPharma Holdings Inc. has 0.7% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Adial Pharmaceuticals Inc.	-15.11%	-38.39%	155.3%	11.22%	0%	-34.18%
Matinas BioPharma Holdings Inc.	18.35%	17.27%	54.07%	200%	27.72%	116.81%

For the past year Adial Pharmaceuticals Inc. has -34.18% weaker performance while Matinas BioPharma Holdings Inc. has 116.81% stronger performance.

Summary

Matinas BioPharma Holdings Inc. beats on 4 of the 6 factors Adial Pharmaceuticals Inc.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid-based drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of aminoglycoside antibiotic agent amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring strategic partnership options for MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.